Solid Biosciences (SLDB) Non Operating Income (2017 - 2026)

Solid Biosciences has reported Non Operating Income for 10 years, with the latest figure at $571000.0 in Q1 2026.

• Quarterly Non Operating Income fell 25.84% year-over-year to $571000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 44.42% YoY) and the FY2025 annual result came in at $4.9 million, down 2.98% from the prior year.
• Non Operating Income climbed to $571000.0 in Q1 2026 per SLDB's latest filing, from -$384000.0 in the prior quarter.
• Over five years, Non Operating Income peaked at $19.4 million in Q4 2022 and troughed at -$2.7 million in Q4 2024.
• A 5-year average of $2.3 million and a median of $2.0 million in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2024: Non Operating Income jumped 46126.19% in 2022, then plunged 240.02% in 2024.
• Over 5 years, Non Operating Income stood at $19.4 million in 2022, then tumbled by 90.06% to $1.9 million in 2023, then slumped by 240.02% to -$2.7 million in 2024, then soared by 85.78% to -$384000.0 in 2025, then surged by 248.7% to $571000.0 in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $571000.0, -$384000.0, and $2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.